Ocular Therapeutix, Inc.
OCUL Healthcare Biotechnology
Ocular Therapeutix, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $52.0 million, down 18.5% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 10.3%, free cash flow fell 25.4% and total debt rose 4.13%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow OCUL
Ocular Therapeutix, Inc. (OCUL) EV/Sales
As of 16 October 2026, Ocular Therapeutix, Inc. (OCUL) trades at a EV/Sales of 19.6×. Over the past ten years it has ranged from 2.2× (November 2023) to 719× (March 2015); the current reading is higher than 31% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 30.9× | 91.79% |
| FY2024 | 16.1× | 258.57% |
| FY2023 | 4.5× | 39.40% |
| FY2022 | 3.2× | (66.54%) |
| FY2021 | 9.6× | (84.33%) |
| FY2020 | 61.5× | 49.72% |
| FY2019 | 41.1× | (33.20%) |
| FY2018 | 61.5× | 7.99% |
| FY2017 | 57.0× | (29.47%) |
| FY2016 | 80.8× | 10.43% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 32.3× | 29.09% |
| Mar 2026 | 25.0× | (19.04%) |
| Dec 2025 | 30.9× | (7.99%) |
| Sep 2025 | 33.6× | 48.81% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ZBIO Zenas BioPharma, Inc. compare | n/m |
| MAZE Maze Therapeutics, Inc. compare | n/m |
| GPCR Structure Therapeutics Inc. Sponsored ADR compare | n/m |
| NUVB Nuvation Bio Inc. compare | 6.7× |
| KRSA Korsana Biosciences, Inc. compare | 8.8× |
| NTLA Intellia Therapeutics, Inc. compare | 18.3× |
| OCUL Ocular Therapeutix, Inc. | 19.6× |
| QURE uniQure N.V. compare | 36.8× |
| STOK Stoke Therapeutics, Inc. compare | 47.2× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)